Macitentan in Pulmonary Hypertension of Sickle Cell Disease

NCT02651272 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Unable to enroll IRB approved sample of participants.

Conditions

Pulmonary Hypertension
Sickle Cell Disease

Interventions

DRUG: macitentan

Sponsor

Boston University

Collaborators

[object Object]